The preimplantation genetic testing market valued at USD 780.8 million in 2023 will reach USD 1.7 billion by 2032

From GlobeNewswire: 2024-12-16 04:30:00

The preimplantation genetic testing market was valued at USD 780.8 million in 2023, projected to grow at a CAGR of 9.4% from 2024 to 2032. Increased awareness of reproductive health and demand for genetic disorder screening in newborns are driving this growth. PGT allows families to detect genetic abnormalities in embryos before implantation, improving reproductive outcomes.

The market is segmented by product and service categories, with the product segment leading in 2023 and expected to grow at a CAGR of 9.3% during 2024-2032. Next-generation sequencing (NGS) holds the largest market share at 42% in 2023 due to its speed, accuracy, and efficiency in detecting genetic abnormalities. The U.S. dominated the North American market in 2023 and is expected to maintain this lead.

With advancements in genetic technologies and increasing focus on reproductive health, the preimplantation genetic testing market is set for steady progression. NGS technology, with its ability to sequence multiple embryos simultaneously, is driving demand. Major players in the market include Illumina, Thermo Fisher Scientific, and Vitrolife Group among others.



Read more at GlobeNewswire: Preimplantation Genetic Testing Market to hit USD 1.7